News

This double-blind, placebo-controlled trial enrolled normal healthy adult volunteers in sequential, dose-escalating cohorts. The Phase I data show that single, oral doses of NGX426 from 40mg to 90mg

Testing of the lead candidates in treated leukemia cell cultures indicated that the JAK2 kinase inhibitors were active against both wild-type and mutant JAK2 kinase activity and caused

Of the 73 evaluable cutaneous T-cell lymphoma (CTCL) patients, an overall response rate of 37% (27/73) was reported, with four complete responses (6%), 23 partial responses (31%) and

The study demonstrated that the uptake, efflux and cytotoxicity of Xanafide were unaffected by MDR proteins expressed in acute myeloid leukemia (AML) cells, and s-AML cells in particular,

In the study, Inno-406 was shown to be well tolerated and demonstrated activity in patients with chronic myelogenous leukemia (CML) who are intolerant or resistant to imatinib and

The acquisition will bring together ImmunoVaccine Technologies (IVT’s) signature VacciMax platform with Immunotope’s portfolio of immunotherapeutic antigens and antigen discovery platform, allowing the new private company to create

These results suggest that a single, confirmatory, Phase III clinical trial could provide sufficient evidence of efficacy provided that it is well designed, well executed and provides clinically

This follows the FDA’s acceptance of a supplemental new drug application (sNDA) seeking expansion to the approved product labeling for Ranexa to include a first-line angina indication and

Expanding upon its technology combining a battery-powered driver and specialty needles to rapidly and safely access the intraosseous space, Vidacare said that it has developed the OnControl biopsy